

PERSONAL INFORMATION

Jeanine Roeters van Lennep

WORK EXPERIENCE

-
- May 2010- Present **Associate professor, internist vascular Medicine, dep Internal Medicine**
Erasmus MC (Netherlands)
Medical Coordinator Vascular Medicine in Cardiovascular Centre, Supervisor vascular genetics clinic and follow-up pre-eclampsia clinic
1.0 fte permanent position (0.5 fte clinical work, 0.33 fte research, 0.17 fte teaching)
- February 2003- 2010 **Resident Internal Medicine, specialization Vascular Medicine**
University Medical Center, Leiden (Netherlands)
- February 2003-September 2003 **Resident Cardiology**
Leiden University Medical Center (Netherlands)
- 2017- Present **Horizon Medication Committee Cardiovascular disorders**
National Health Care institute (Zorginstituut) the Netherlands (Netherlands)
- 2017- Present **Supervisory Board**
HeartLife clinics (Netherlands)

EDUCATION AND TRAINING

-
- June 2019- **Associate Professor**
Erasmus MC (Netherlands)
cardiovascular medicine
- 2003- **Registration as MD**
Leiden University (Netherlands)
- 2001- 2003 **Medical Internships**
(Netherlands)
- 1997- 2001 **Research fellow, Dep Cardiology**
Leiden University Medical Center (Netherlands)
- 1995- 1999 **MSc degree in Medicine**
Leiden University (Netherlands)
- 1994- 1995 **Comparative Literary Studies/Linguistics**
University of Kent at Canterbury (Netherlands)
- **Doctorate**
Leiden University (Netherlands)
Gender and cardiovascular disease: risk factors, diagnosis and treatment University, Promotor: prof dr E.E. van der Wall,

ADDITIONAL INFORMATION

- Expertise**
1. dyslipidemia
 - Familial Hypercholesterolemia
 - Familial Chylomcronemia syndrome
 - other (hereditary) dyslipidemia
 2. sex and gender medicine
 3. Cardiovascular disease

Publications International refereed journals:

Publications 2016-2020

1. Benschop L, Brouwers L, Zoet GA, Meun C, Boersma E, Budde RPJ, Fauser BCJM, de Groot CMJ, van der Schouw YT, Maas AHEM, Velthuis BK, Linstra KM, Kavousi M, Duvekot JJ, Franx A, Steegers E, van Rijn BB, Roeters van Lennep JE; CREW Consortium. Early Onset of Coronary Artery Calcification in Women With Previous Preeclampsia Circ Cardiovasc Imaging 2020 Nov;13(11):e010340.doi: 10.1161/CIRCIMAGING.119.010340.
2. Sleutjes JAM, de Vries AC, van der Woude CJ, Roeters van Lennep JE. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflamm Bowel Dis. 2020 Nov 6:izaa295. doi: 10.1093/ibd/izaa295.
3. Al Fatty Z, Beckers FLM, Sjauw KD, Roeters van Lennep JE, Schreuder MM. Catamenial chest pain and spontaneous coronary artery dissection: A case report. Case Rep Womens Health 2020 Sep 28;28:e00256.
4. Adank MC, Benschop L, Kors AW, Peterbroers KR, Smak Gregoor AM, Mulder MT, Schalekamp-Timmermans S, Roeters Van Lennep JE, Steegers EAP. Maternal lipid profile in early pregnancy is associated with foetal growth and the risk of a child born large-for-gestational age: a population-based prospective cohort study : Maternal lipid profile in early pregnancy and foetal growth. BMC Med. 2020 Oct 2;18(1):276.
5. Wekker V, van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, Laven JSE, Roeters van Lennep JE, Roseboom TJ, Hoek A. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020 Nov 1;26(6):942-960.
6. Mikolic A, van Klaveren D, Oude Groeniger J, Wiegers EJA, Lingsma HF, Zeldovich M, von Steinbuchel N, Maas AIR, Roeters van Lennep JE, Polinder S; CENTER-TBI Participants and Investigators. Differences between Men and Women in Treatment and Outcome after Traumatic Brain Injury. J Neurotrauma. 2020 Oct 19. doi: 10.1089/neu.2020.7228.
7. van der Aalst CM, Denissen SJAM, Vonder M, Gratama JWC, Adriaansen HJ, Kuijpers D, Vliegenthart R, Roeters van Lennep JE, van der Harst P, Braam RL, van Dijkman PRM, van Bruggen R, Oudkerk M, de Koning HJ. Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial. Eur Heart J Cardiovasc Imaging. 2020 Oct 20;21(11):1216-1224
8. Denissen SJ, van der Aalst CM, Vonder M, Gratama JWC, Adriaansen HJ, Kuijpers D, Roeters van Lennep JE, Vliegenthart R, van der Harst P, Braam RL, van Dijkman PR, Oudkerk M, de Koning HJ. Screening for coronary artery calcium in a high-risk population: the ROBINSCA trial Eur J Prev Cardiol. 2020 Jun 17:2047487320932263. doi: 10.1177/2047487320932263.
9. Sari G, Meester EJ, van der Zee LC, Wouters K, Roeters van Lennep J, Peppelenbosch M, Boonstra A, Van der Heiden K, Mulder MMT, Vanwollegheem T. A mouse model of humanized liver shows a human-like lipid profile, but does not form atherosclerotic plaque after western type diet. Biochem Biophys Res Commun. 2020 Apr 2;524(2):510-515. IF 2.7
10. Gunning MN, Meun C, van Rijn BB, Daan NMP, Roeters van Lennep JE, Appelman Y, Boersma E, Hofstra L, Fauser CGKM, Rueda-Ochoa OL, Ikram MA, Kavousi M, Lambalk CB, Eijkemans MJC, Laven JSE, Fauser BCJM; CREW consortium. The cardiovascular risk profile of middle age women previously diagnosed with premature ovarian insufficiency: A case-control study. PLoS One. 2020 Mar 5;15(3):e0229576 IF 2.8
11. Schreuder MM, Badal R, Boersma E, Kavousi M, Roos-Hesselink J, Versmissen J, Visser LE, Roeters van Lennep JE. Efficacy and Safety of High Potent P2Y12 Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex-Specific Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020 Feb 18;9(4):e014457 IF 4.5
12. Lagerweij GR, Brouwers L, De Wit GA, Moons K, Benschop L, Maas A, Franx A, Wermer M, Roeters van Lennep JE, van Rijn BB, Koffijberg H. Impact of preventive screening and lifestyle

- interventions in women with a history of preeclampsia: A micro-simulation study. *Eur J Prev Cardiol.* 2020 Feb 13;2047487319898021. doi: 10.1177/2047487319898021. [Epub ahead of print] IF 5.6
13. Singh SS, Roeters van Lennep JE, Lemmers RFH, van Herpt TTW, Lieverse AG, Sijbrands EJG, van Hoek M. Sex difference in the incidence of microvascular complications in patients with type 2 diabetes mellitus: a prospective cohort study. *Acta Diabetol.* 2020 Feb 5. doi: 10.1007/s00592-020-01489-6. [Epub ahead of print] IF 3.0
14. Mulder JWCM, Galema-Boers AMH, de Jong-Verweij LM, Hazelzet JA, Roeters van Lennep JE. The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health. *Atherosclerosis.* 2020 Jan;293:11-17, IF 4.3
15. Benschop L, Schelling SJ, Duvekot JJ, Roeters van Lennep JE Cardiovascular health and vascular age after severe preeclampsia: A cohort study. *Atherosclerosis* 292 (2020) 136-142 IF 4.3
16. Ramaswami U, Futema M, Bogsrud MP, Holven KB, Roeters van Lennep J, Wiegman A, Descamps OS, Vrablik M, Freiburger T, Dieplinger H, Greber-Platzer S, Hanauer-Mader G, Bourbon M, Drogari E, Humphries SE. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. *Atherosclerosis.* 2020 Jan;292:178-187, IF 4.3
- 2019
17. Hermans M, Lennep JRV, van Daele P, Bot I. Mast Cells in Cardiovascular Disease: From Bench to Bedside. *Int J Mol Sci.* 2019 Jul 10;20(14). pii: E3395 IF 4.2
18. Schreuder MM, Sunamura M, Roeters van Lennep JE. Supraventricular tachycardia and the menstrual cycle. *Case Rep Womens Health.* 2019 Oct 22;24:e00153.
19. Hoogendoorn A, den Hoedt S, Hartman EMJ, Krabbendam-Peters I, Te Lintel Hekkert M, van der Zee-van Vark L, van Gaalen K, Witberg KT, Dorst K, Ligthart JMR, Drouet L, Van der Heiden K, van Roeters van Lennep J, van der Steen AFW, Duncker DJ, Mulder MT, Wentzel JJ. Variation in Coronary Atherosclerosis Severity Related to a Distinct LDL (Low-Density Lipoprotein) Profile: Findings From a Familial Hypercholesterolemia Pig Model. *Arterioscler Thromb Vasc Biol.* 2019 Sep 26:ATVBAHA119313246. doi: 10.1161/ATVBAHA.119.313246. [Epub ahead of print] IF 6.6
20. Meun C, Gunning MN, Louwers YV, Peters H, Roos-Hesselink J, Roeters van Lennep J, Rueda Ochoa OL, Appelman Y, Lambalk N, Boersma E, Kavousi M, Fauser BC, Laven JS; CREW consortium, *Clin Endocrinol (Oxf).* 2019 Oct 22. doi: 10.1111/cen.14117. IF 2.9
21. Brouwers JRBJ, Roeters van Lennep JE, Beinema MJ. Biosimilars of Low Molecular Weight Heparins- Relevant Background Information for your Drug Formulary. *Br J Clin Pharmacol.* 2019 Aug 4. doi: 10.1111/bcp.14081 IF 4.2
22. Benschop L, Schalekamp-Timmermans S, Schelling SJC, Steegers EAP, Roeters van Lennep JE. Early Pregnancy Cardiovascular Health and Subclinical Atherosclerosis. *J Am Heart Assoc.* 2019 Aug 6;8(15):e011394. doi: 10.1161/JAHA.118.011394. IF 4.7
23. Narverud I, Bogsrud MP, Oril LKL, Ulven SM, Retterstol K, Ueland T, Mulder M, Roeters van Lennep JE, Halvorsen B, Aukrust P, Veierod MB, Holven KB. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. *Br J Nutr.* 2019 Jul 2;1-24. IF 3.3
24. Yahya R, Berk K, Verhoeven A, Bos S, van der Zee L, Touw J, Erhart G, Kronenberg F, Timman R, Sijbrands E, Roeters van Lennep J, Mulder M. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. *Atherosclerosis.* 2019 Jul 3. pii: S0021-9150(19)31392-9. doi: 10.1016/j.atherosclerosis.2019.07.001 IF 4.3
25. Bekkering S, Stiekema LCA, Bernelot Moens S, Verweij SL, Novakovic B, Prange K, Versloot M, Roeters van Lennep JE, Stunnenberg H, de Winther M, Stroes ESG, Joosten LAB, Netea MG, Riksen NP. Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. *Cell Metab.* 2019 Jul 2;30(1):1-2 IF 19.3
26. Gunning MN, Meun C, van Rijn BB, Maas AHM, Benschop L, Franx A, Boersma E, Budde RPJ, Appelman Y, Lambalk CB, Eijkemans MJC, Velthuis BK, Laven JSE, Fauser BCJM; CREW-consortium Coronary artery calcification in middle-aged women with premature ovarian insufficiency. *Clin Endocrinol (Oxf).* 2019 May 2. doi: 10.1111/cen.14003 IF 2.9
27. Benschop L, Duvekot JJ, Roeters van Lennep JE, Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. *Heart.* 2019 Jun 7. pii: heartjnl-2018-313453. doi: 10.1136/heartjnl-2018-313453. IF 5.4
28. Adank MC, Benschop L, Peterbroers KR, Smak Gregoor AM, Kors AW, Mulder MT, Schalekamp-Timmermans S, Roeters Van Lennep JE, Steegers EAP. Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum? *Am J Obstet Gynecol.* 2019 Mar 30. pii: S0002-9378(19)30527-7. doi:

10.1016/j.ajog.2019.03.025 IF 6.2

29. Bot I, Mulder MT, Indhirajanti S, van Daele PLA, Roeters van Lennep JE Reply to: "The "cholesterol paradox" in patients with mastocytosis". *Atherosclerosis*. 2019 May;284:262-263 IF 4.3
30. Benschop L, Schalekamp-Timmermans S, Broere-Brown ZA, Roeters van Lennep JE, Jaddoe VVW, Roos-Hesselink JW, Ikram MK, Steegers EAP, Roberts JM, Gandley RE. Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy. *Circulation*. 2019 Apr 2;139(14):1698-1709. IF 23.0
31. Dam, V; Onland-Moret, NC; Verschuren, WMM; Boer, JM A; Benschop, L; Franx, A; Moons, KGM; Boersma, E; van der Schouw, YT on behalf of CREW consortium (J.Roeters van Lennep) Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy.
Heart (British Cardiac Society) Published: 2018-Sep-12 (Epub 2018 Sep 12), IF 5.4
32. Gurgoze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, Roeters van Lennep JE. Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience *Clin Pharmacol Ther*. 2019 Feb;105(2):496-504,IF 6.5
2018
33. Schol-Gelok S, Galema-Boers JAMH, van Gelder T, Kruip MJHA, Roeters van Lennep JE, Versmissen J. No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia. *Biomed Pharmacother*. 2018 Dec;108:1412-1414 IF 3.5
34. Benschop L, Schalekamp-Timmermans S, Roeters van Lennep JE, Jaddoe VVW, Steegers EAP, Ikram MK. Cardiovascular Risk Factors Track From Mother to Child. *J Am Heart Assoc*. 2018 Oct 2;7(19):e009536. IF 4.5
35. Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JHW, de Graaf J, Visseren FLJ, Imholz BPM, Roeters van Lennep JE, Huijgen R, Kastelein JJP, Hovingh GK. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. *J Clin Lipidol*. 2018 Jul - Aug;12(4):972-980, IF 5.8
36. Bergen NE, Schalekamp-Timmermans S, Roos-Hesselink J, Roeters van Lennep JE, Jaddoe VVW, Steegers EAP Hypertensive disorders of pregnancy and subsequent maternal cardiovascular health. *Eur J Epidemiol*. 2018 Aug;33(8):763-771. IF 7.0
37. Davidson M, Stevenson M, Hsieh A, Ahmad A, Roeters van Lennep J, Crowson C, Witztum J The burden of Familial Chylomicronemia Syndrome: Results from the Global-INFOCUS Study *J Clin Lipidol*. 2018 Jul - Aug;12(4):898-907, IF 5.8
38. KB. Holven, I Narverud, J Roeters van Lennep, J Versmissen, LKL Oyri, A Galema-Boers, G Langslet, SM Ulven, MB. Veierod, K Retterstol, MP Bogsrud. ex differences in cholesterol levels from birth to 19 years of age may explain equal onset of CHD in males and females with FH *J Clin Lipidol*. 2018 2018 May 12:748-755: IF 5.8
39. Galema-Boers AM, Lenzen MJ, Engelkes SR, Sijbrands EJ, Roeters van Lennep JE Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy *J Clin Lipidol*. 2018 Mar - Apr;12(2):409-416, IF 5.8
40. L. Benschop, NE Bergen, S Schalekamp-Timmermans, VVW Jaddoe, MT Mulder, EAP Steegers, JE Roeters van Lennep Lipid profile six years after gestational hypertension and pre-eclampsia. *J Clin Lipidol*. 2018 Mar - Apr;12(2):428-436 IF 5.8
41. GA. Zoet, H Benschop, E Boersma, RPJ Budde, BCJM. Fauser, Y van der Graaf, CJM de Groot, AHM Maas, JE Roeters van Lennep, EAP Steegers, FL Visseren, BB van Rijn, BK. Velthuis, A Franx, on behalf of the CREW consortium. Prevalence of subclinical coronary artery disease assessed by coronary computed tomography angiography in women with a history of preeclampsia aged 45 to 55 years. *Circulation*. 2018 Feb 20;137(8):877-879, IF 19.3
42. L. D'Erasmus, I. Minicocci, A. Nicolucci A, P Pintus P, J. Roeters van Lennep, L. Masana, P Mata, RM Sanches-Hernandez, P. Prieto-Matos, JT Real, JF Acaso, EE Lafunete, M Pocovi, FJ Funetes, S Muntoni, S. Bertolini, C. Sirtori, L. Calabresi, C. Pavanello, M. Averna, A.B. Cefalu, D. Noto, A. Pacifico, G. Pes, M Harada-Shiba, E. Manzato, S. Zambon, A Zambon, A Vogt, M Scardapane, B Sjouke, R, Fellin, M. Arca ong term cardiovascular outcomes in patients with autosomal recessive hypercholesterolemia (ARH). *J Am Coll Cardiol*. 2018 Jan 23;71(3):279-288 IF 16.5
43. Benschop L, Duvekot JJ, Versmissen J, van Broekhoven V, Steegers EAP, Roeters van Lennep JE Blood pressure profile one year after severe pre-eclampsia. *Hypertension*. 2018

Mar;71(3):491-498, IF 6.9

44. Indhirajantia S, van Daele PLA, Bos S, Mulder MT, Bot I, Roeters van Lennep JE Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels.

Atherosclerosis, 2018 Jan;268:152-156. IF 4.5

45. CM. Beukhof, ET. Massolt, TJ. Visser, TIM. Korevaar, M. Medici, WW. de Herder, JE. Roeters van Lennep, MT. Mulder, YB. de Rijke, C. Reiners, FA. Verburg, RP. Peeters, Effects of thyroid stimulating hormone on peripheral thyroid hormone metabolism and serum lipids

Thyroid 2018 28(2):168-174, IF 5.5

46. 16. J.Roeters van Lennep Women are not small men Maturitas. 2018 Jan;107:A3-A4, IF 3.3

2017

47. MM. van Schie, S. Jainanuning, J.E. Roeters van Lennep Monogenetic disorders of the cholesterol metabolism and premature cardiovascular disease

Eur J Pharmacol. 2017 Dec 5;816:146-153 , IF 2.9

48. Benschop L, Schalekamp-Timmermans S, Roeters van Lennep JE, Jaddoe VVW, Wong TY, Cheung CY, Steegers EAP, Ikram KM Gestational hypertensive disorders and retinal microvasculature: the Generation R Study. BMC Med. 2017 Aug 14;15(1):153. IF 8.1

49. Zoet GA, Meun C, Benschop L, Boersma E, Budde RPJ, Fauser BCJM, de Groot CJM, van der Lugt A, Maas AHM, Moons KGM, Roeters van Lennep JE, Roos-Hesselink JW, Steegers EAP, van Rijn BB, Laven JSE, Franx A, Velthuis BK. Cardiovascular RiskprofilE - IMaging and gender-specific disOrders (CREw-IMAGO): rationale and design of a multicenter cohort study

BMC Womens Health. 2017 Aug 7;17(1):60, IF 2.1

50. T Katrien J Groenhof, Bas B van Rijn, Arie Franx, Jeanine E Roeters van Lennep, Michiel L Bots, A Titia Lely Preventing cardiovascular disease after hypertensive disorders of pregnancy: searching for the how and when? Eur J Prev Cardiol. 2017 Nov;24(16):1735-1745. IF 4.5

51. Saleh L, van den Meiracker AH, Geensen R, Kaya A, Roeters van Lennep JE, Duvekot JJ, Verdonk K, Steegers EAP, Russcher H, Danser JAH, Visser W.s Flt-1 and PIGF kinetics during and after pregnancy in women with suspected or confirmed preeclampsia. Ultrasound Obstet Gynecol. 2017 Jun 10, IF 4.7

52. Stefanutti C, Julius U, Watts GF, Harada-Shiba M, Cossu M, Schettler VJ, De Silvestro G, Soran H, Roeters van Lennep JE, Pisciotto L, Klor HU, Widhalm K, Moriarty PM; MIGHTY MEDIC Toward an international consensus Integrating lipoprotein apheresis and new lipid-lowering drugs.Multinational Society. J Clin Lipidol. 2017 Jul - Aug;11(4):858-871 IF 5.8

53. Sharifi M, Higginson E, Bos S, Gallivan A, Harvey D, Li KW, Abeysekera A, Haddon A, Ashby H, Shipman KE, Cooper JA, Futema M, Roeters van Lennep JE, Sijbrands EJJ, Labib M, Nair D, Humphries SE. Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia Atherosclerosis, 2017 Aug;263:405-411 IF 4.5

54. R. Vongpromek, S. Bos, G.J.R. ten Kate, H. Bujo, M. Jiang, K. Nieman, W. Schneider, J.E. Roeters van Lennep, A.J.M.Verhoeven, E. J.G. Sijbrands, M.T. Mulder. Soluble LR11 associates with aortic root calcification in asymptomatic treated patients with familial hypercholesterolemia Atherosclerosis. 2017 Oct;265:299-304., IF 4.5

55. K.A. Berk, R Yahya, A.J.M. Verhoeven, J. Touw, F. Leijten, E.F.C. van Rossum, V.L. Wester, M.A. Lips, H. Pijl, B. Ozcan, R. Timman, G. Erhart, F Kronenberg, J.E. Roeters van Lennep, E.J.G. Sijbrands, M.T. Mulder. Effect of body weight reduction on Lp(a) levels in obesity and type 2 diabetes Diabetologia 2017 Jun;60(6):989-997 IF 6.3

56. J.M.H. Galema-Boers, M.J. Lenzen, E.J. Sijbrands, J.E. Roeters van Lennep. Proprotein convertase subtilisin / Kexin 9 inhibition in patients with Familial Hypercholesterolemia: initial clinical experience J Clin Lipidol. 2017 11(3):674-681, IF 5.8

57. B. Sjouke, R. Yahya, M.W.T. Tanck, J.C. Defesche, J. de Graaf, A. Wiegman, J.J.P. Kastelein, M.T. Mulder, G.K. Hovingh, J.E. Roeters van Lennep Plasma Lipoprotein(a) levels in Patients with Homozygous Autosomal Dominant Hypercholesterolemia. J Clin Lipidol. 2017:507-514. IF 5.8

58. R. Yahya, M.T. Mulder, E.J.G. Sijbrands, M. Williams, J.E. Roeters van Lennep LDL-receptor negative compound heterozygous familial hypercholesterolemia: Two lifetime journeys of lipid lowering therapy J Clin Lipidol. 2017: 301-305 I IF 5.8

59. L.Louter, J. Defesche, J.E. Roeters van Lennep Cascade screening for familial hypercholesterolemia: practical consequences Atheroscler Suppl. 2017 Nov;30:77-85, IF 4.5

2016

60. Bos S, Duvekot MH, Ten Kate GR, Verhoeven AJ, Mulder MT, Schinkel AF, Nieman K, Watts GF, Sijbrands EJ, Roeters van Lennep JE Carotid artery plaques and intima medial thickness in familial hypercholesterolemia patients on long-term statin therapy: A case control study. *Atherosclerosis*. 2016 Dec 2;256:62-66. IF 4.5
61. L. Masana, Roeters van Lennep JE Dose wisely! How lipid-lowering undertreatment can lead to overtreatment *Atherosclerosis*. 2016 Dec 2;256:62-66. IF 4.5
62. Sjouke B, Defesche JC, Hartgers ML, Wiegman A, Roeters van Lennep JE, Kastelein JJ, Hovingh GK. Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease *J Clin Lipidol*. 2016 Nov - Dec;10(6):1462-1469, IF 5.8
63. Roeters van Lennep JE. Knowledge equals health; why all healthcare professionals should know about familial hypercholesterolemia *Atherosclerosis*. 2016 Sep;252:188-9, IF 4.5
64. N.M.P Daan, T. Muka, M.P.H. Koster, J.E. Roeters van Lennep, C.B. Lambalk, J.S.E. Laven, C.G.K.M. Fauser, C. Meun, Y.B. de Rijke, H. Boersma, O.H. Franco, M. Kavousi, B.C.J.M. Fauser Cardiovascular risk in women with premature ovarian insufficiency compared to premenopausal women at middle age *J Clin Endocrinol & Metabol*, 2016 Sep;101(9):3306-15 IF 6.2
65. KY. Heida, ML. Bots, CJM. de Groot, FM. van Dunne, M. Cohen, NM. Hammoud, A. Hoek6, J S.E. Laven, AH.E.M. Maas, JE. Roeters van Lennep, BK. Velthuis, TA. van Barneveld, A. Franx Cardiovascular risk management after reproductive and pregnancy related disorders a Dutch multidisciplinary evidence based guideline *Eur J Prev Cardiol*. 2016 Nov;23(17):1863-1879, IF 4.5
66. R. Yahya, E. Favari, L Calabresi, A.J Verhoeven, F. Zimetti, MP Adorni, M Gomaraschi, M. Averna, A.B Cefalu, F. Bernini, EJ Sijbrands, M.T Mulder, JE Roeters van Lennep *Atherosclerosis*. 2016 Aug;251:15-8., IF 4.5
67. Dedic A, Ten Kate GJ, Roos CJ, Neefjes LA, de Graaf MA, Spronk A, Delgado V, Roeters van Lennep JE, Moelker A, Ouhlous M, Scholte AJ, Boersma E, Sijbrands EJ, Nieman K, Bax JJ, de Feijter PJ. Prognostic Value of Coronary Computed Tomography Imaging in Patients at High Risk Without Symptoms of Coronary Artery Disease. *Am J Cardiol*. 2016 Mar 1;117(5):768-74, IF 3.3
68. KPJ Wijnands, EM van Uitert, RA Visser, JE Roeters van Lennep, AHJ Koning, AGMGJ Mulders, JSE Laven, EAP Steegers, RPM Steegers-Theunissen. The periconception maternal cardiovascular risk profile influences human embryonic growth trajectories in IVF/ICSI pregnancies *Hum Reprod*. 2016 Jun;31(6):1173-81, IF 4.6
69. J.E. Roeters van Lennep, K.Y. Heida, M.L. Bots, A. Hoek on behalf of the collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis *Eur J Prev Cardiol*. 2016 Jan;23(2):178-86 IF 4.5

Projects grants

- 2022 Helping the patient with high cardiovascular risk choose: developing a shared decision making tool (Novartis, applicant PI, 100K euro)
- 2022 Cholesterol, Ovarian Reserve and Menopause: finding the missing link (Erasmus MC, applicant PI 50K euro)
- 2021 IMPRESS consortium (Dutch Heart Foundation, work package leader, 2500k euro)
- 2020 Everything has a rhythm, prevention of atrial fibrillation and its complication in women and men, ZonMW (50K euro, co-PI)
- 2019 Dietary prevention of cholesterol induced trained immunity in early atherosclerosis, University of Oslo, PI prof Holven (1700K euro, project member)
- 2019 My digital twin, Convergence for Health and Technology Erasmus MC, TU Delft (300K euro project member)
- Clinical trials:
- Previous trial experience
- 2021-present ORION-13 trial NCT04659863 (PI)
- 2021-present ORION-16 trial NCT04652726 (PI)
- 2021 -present IONIS-CS3 Balance NCT04568434 (PI)
- 2019-present EVOLVE (NCT03811223) (PI)
- 2017-present FHGTOOI and FHGT002 A Gene Therapy Study for Homozygous Familial

Hypercholesterolemia (NCT02651675) (HoFH) (PI)
'2015-present LOWER study, (NCT02135705) (hoFH) Aegerion (PI)
2014- 2017 TAUSSIG trial (NCT01624142) (hoFH/severe hem-I) Amgen (subPI)
2014- 2018 SPIRE-FH trial (NCT01968980) (heFH), Pfizer (subPI)
2014-2016 GAUSS-3 (NCT01968980) (statin intolerance, Amgen (subPI)
2013- 2017 FOURIER trial (NCT01764633) (heFH/CVD) Amgen (subPI)
2012- 2018 ODYSSEY trial (NCT01709500) (heFH), Sanofi (subPI)

Memberships

Board Memberships- Scientific Societies

2021- present board member Executive Committee European Atherosclerosis Society (EAS)
2017-present Board member Dutch Society of Gender and Health (Nederlandse Vereniging Gender en Gezondheid, NVG&G)
2017-2018 Board member Dutch Society Internists Vascular Medicine (NVIVG), responsible for quality and guidelines
2016-2018 Board member Henny Verhagen Foundation
2015-present Board member National Lipid Academy
2014-present Chair Working group Dyslipidemia
Dutch Society for Vascular Medicine (NVIVG)
2013- present Board member National Alliance of Gender & Health
(Scientific) advisory Board Membership
2020 Advisory Board LEEFH (National Expert Centre for Hereditary Dyslipidemia)
2020-present Scientific Advisory Board Dutch Heart Foundation
2014- 2020 Scientific Advisory Board LEEFH (National Expert Centre for Hereditary Dyslipidemia)
2019-p2022 Chair Dutch Society for Internists Vascular Medicine (NVIVG), national society for internists vascular medicine)
Review Board Membership
2019-present Review board Corrie Hermann Prize (VNVA Dutch Society of Female Physicians)
2018- present Review board European Science Foundation

Other Academic activities

2017- present Chair Horizon Committee for cardiovascular drugs, National Health Institute
2016-present Chair Academic Centre GESTURE (Gender Specific Translational research Union Rotterdam, Erasmus MC)
2015-2018 Board member Rotterdam Academic Specialist Association (RASV)
2014- present Pre-program committee ZonMW Knowledge program "Gender & Health"

Guideline committees:

2019-present Revision Multidisciplinary guideline "Cardiovascular risk management after reproductive disorders- Dutch Society of Obstetrics and Gynaecology
Position: Member of guideline committee, Delegate Dutch Society of Internists (NIV)
2015-2018 Multidisciplinary guideline "(Hereditary) Dyslipidemia" Dutch Society of Internal Medicine (NIV)
Position: Chair guideline committee

Other Relevant Information

Research experience/academic record

My motivation is to improve cardiovascular prevention by performing multidisciplinary clinical and translational research with a focus on populations at high risk of cardiovascular disease:

1. Sex and gender-specific medicine - improving women's health with special focus on cardiovascular risk in women with reproductive disorders such as polycystic ovary syndrome, premature ovarian insufficiency and pre-eclampsia

Main research topics

- Establishing and improving cardiovascular risk

Projects: CREW project (Dutch Heart Foundation), Cardiovascular risk profile in generation R mothers), cycle study to assess influence of menstrual cycle on cardiac symptoms, Diverse projects in collaboration with Dep Gynaecology and Dep Epidemiology.

Patient care and research is intertwined at all levels: all patients are biobanked and clinical characteristics and follow-up information are entered in databases, patients participate in clinical trials and registries of novel medication and participate in investigator initiated translational and clinical research. My research is by nature multidisciplinary with collaboration with o.a cardiologists, gynaecologists, epidemiologists and basic scientists.

Grants

Principal investigator

2017 Dutch Heart Foundation 82,4K euro

Innovation grant/crowd funding: Cardiac symptoms and menstruation: a risky period (the cycle study)

2017 Dutch Heart Foundation, 100K euro

Sex-specific net clinical effect of the "Big Five "cardiovascular drugs: systematic review and quantitative meta-analysis

2015 MRACE 2014-pilot project, 50K euro

Residual cardiovascular disease risk: lessons to learn from an optimal small animal Model

2014 Sanofi, Investigator initiated grant, 34K euro

Goal attainment in primary and secondary prevention in heterozygous FH patients

Co-investigator

2014 Dutch Heart Foundation , 2200K euro

National consortium to promote CardiovasculaR hEalthy aging in Women (CREW)

Professional activities

2016-present Board member Henny Verhagen Foundation (dedicated to women & health)

2015-present Board member National Lipid Academy

2015-present Multidisciplinary guideline " (Hereditary) Dyslipidimia" (chair)

2014-present Scientific Board Stichting LEEFH (National FH foundation)

2014 present ZonMW Knowledge program "Gender and Health" Pre-program committee

2013- 2017 Member Dutch Alliance Gender and health

2012-2014 Multidisciplinary guideline "Cardiovascular risk management after reproductive disorders, Member of guideline committee, Delegate NIV (Dutch Internist Society)

National/international activities

2014-present Working group Dyslipidemia (chair)

Dutch Society of Vascular Medicine (NVIVG)

2015-present Mighty (Medics Multidisciplinary International Group for Hemapheresis

TherapY and MEtabolic DIsturbances Contrast)

Country representative for the Netherlands

Honors and awards

2015 Corrie HermannAward Dutch female doctors (VnVA): best Dutch female diversity researcher 2015

2013 Young investigator poster prize, Annual congress Scandinavian Society of Atherosclerosis, Humblebaek, Denmark

2012 Erasmus MC Leadership program for talented young clinicians

2001 Dick Held Prize 2001- KNMG Leiden

Gender and Cardiovascular Disease; Risk factors, diagnosis and treatment

1999 Hippocrates Study Prize 1999- Hippocrates Foundation